What question did this study set out to answer?

This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.

synapse

⌘+K

synapse

⌘+K

April 10, 2026

SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2-3 trials

Key Points

This research aims to evaluate the SLE-DAS responder index as a reliable outcome measure in SLE trials.
Assessment of the SLE-DAS RI in phase 2-3 trials of anifrolumab.
Comparison of SLE-DAS RI with other efficacy endpoints.
Evaluation of improvements in patient-reported outcomes.
SLE-DAS RI demonstrates robust performance as an efficacy endpoint.
Associated with sustained disease control over time.
Facilitates accurate identification of meaningful outcomes in trial design.

Abstract

The SLE-DAS RI is a robust efficacy end point in SLE trials, associated with sustained disease control and meaningful improvements in patient-reported outcomes. SLE-DAS also enables accurate identification of MSDA, supporting its broader utility in trial design.

Mark Helpful

Bookmark

Relay